Link Technologies Ltd has launched two new modified phosphoramidite ranges to complement its existing portfolio of products to support oligonucleotide synthesis. For triplex, antisense and gene targeting studies, the new RNA-type phosphoramidites provide nuclease resistance and stability, while the new ethyl phosphoramidites improve oligonucleotide stability and delivery into cells, making them ideal for therapeutic applications.
Link Technologies Launches New Products for Oligonucleotide Synthesis
Building on from the existing range of standard nucleobase RNA phosphoramidites and CPG supports, the modified RNA-type phosphoramidites comprise two new 2’-OMe RNA products, 2’-OMe-I and 2’-OMe-T. Oligonucleotides containing these modifications are ideal for triplex, antisense and gene targeting studies, as they form more stable hybrids with complementary RNA strands compared to equivalent DNA or RNA strands. Furthermore, when used in gene targeting studies, the addition of 2’-OMe residues into triplex forming oligonucleotides (TFO’s), confers the same nuclease resistance and stability as seen with duplexes.
Oligonucleotides synthesised from Link’s new ethyl phosphoramidites (available with standard nucleobase protection) have a neutral charge and slightly lipophilic character, which improves their delivery into cells. They are ideal for use in therapeutic applications as oligonucleotides containing these ethyl groups are nuclease resistant and have been shown to inhibit protein expression and cell growth when taken up by liposomes.
Dr Catherine McKeen, Technical Manager at Link Technologies, commented: “We understand the importance of evolving our product offering to reflect the developing needs of our customers. As part of this, the new modified phosphoramidites provide increased nuclease resistance and stability, extending the experimental capabilities available to our customers.”
Company websiteLink Technologies Ltd.